Serum Institute of India has applied to the country's drug regulator and the health ministry for full approval of its Covid-19 vaccine Covishield, the company's chief executive said.
Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.
The Indian government now has enough data to consider a full market authorisation, Serum Institute CEO Adar Poonawalla said on Twitter.
